

Oct 19th Room A10月18日(金)
プログラム10月19日(土)
プログラム10月20日(日)
プログラム

特別企画

シンポジウム

ガイドライン
セッションアフレックス
ミラクルランチ

技術講習会

ESFA
Workshop世界の
アフレックス事情一般演題
(英語口演)一般演題
(日本語口演)一般演題
(ポスター)

セミナー

索引

Symposium 8 Critical Care Medicine クリティカル領域 9:00~10:30

Chair Takeshi Moriguchi Faculty of Medicine, University of Yamanashi
Chair Xiuming Xi Past President of CSCCM, China

SY8-01 Dose of CRRT in AKI: The Other Way Around

Bin Du
Medical ICU, Peking Union Medical College Hospital, China

SY8-02 Apheresis for Sepsis

Takeshi Moriguchi
Department of Emergency and Critical Care Medicine, University of Yamanashi
School of Medicine, Yamanashi, Japan

SY8-03 The application of the column adsorbing LAP positive cells to therapy of sepsis-induced immune paralysis.

Kazuo Teramoto
Department of Pathology, Shiga University of Medical Science, Japan

SY8-04 Early Prediction of Acute Kidney Injury in ICU

Haibo Qiu
Nanjing Zhongda hospital, Southeast University, China

Symposium 9 PMX 10:45~12:15

Update report, PMX on sepsis

Chair Tohru Tani Department of Research and Development for Innovative Medical
Devices and Systems, Shiga University of Medical Science
Chair Hisataka Shoji Toray Medical Co.SY9-01 Impact of timing of polymyxin B immobilized fiber column direct hemoperfusion
on outcome in patients with septic shockTomoki Tanaka
Shiga University of Medical Science Emergency and Intensive Care Unit, Shiga,
Japan,

SY9-02 Blood purification for septic shock patients

Toshiaki Ikeda
Division of Critical Care Medicine Tokyo Medical University, Hachioji Medical
Center, Japan

SY9-03 Role of Rescue therapy using Polymyxin B Hemoperfusion in immunocompromised hosts with refractory septic shock

Sang-Bum Hong
Department of Pulmonary and Critical Care Medicine, Asan Medical Center in Seoul,
Univ. of Ulsan, College of Medicine, KoreaSY9-04 The case for using PMX in critically ill patients - Don't through out the baby
with the bath waterSean M Bagshaw
Critical Care Medicine, University of Alberta, Canada

Luncheon Seminar 4

12:30~13:30

Sponsored by Asahi Kasei Medical 旭化成メディカル株式会社

Pathogenic Antibodies and Lipoproteins - Current Trends in Therapeutic Apheresis

Chair Hidenori Matsuo National Hospital Organization, Nagasaki National Hospital

LS4-01 Pathogenic Antibodies and Lipoproteins - Current Trends in Therapeutic Apheresis

Reinhard Klingel

Apheresis Research Institute, Cologne and 1st Department of Internal Medicine, University of Mainz, Germany

Guideline Session 1 ガイドライン 1

13:40~15:30

Chair Hidenori Matsuo National Hospital Organization, Nagasaki National Hospital

GS1-01 The JSFA clinical practice guideline for Therapeutic Apheresis

Takaya Abe

Department of Urology, Iwate Medical University, Iwate, Japan

GS1-02 The Chapter for the Kidney Diseases, the Japanese Society for Apheresis Guideline

Norio Hanafusa

Department of Blood Purification, Tokyo Women's Medical University, Tokyo, Japan

GS1-03 Clinical practice guidelines for therapeutic apheresis in emergency and critical care

Hajime Nakae

Department of Emergency and Critical Care Medicine, Akita University Graduate School of Medicine, Japan

GS1-04 The apheresis guidelines for digestive diseases

Kazuaki Inoue

Division of Gastroenterology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan

Tomoki Furuya

Department of Emergency and Critical Care Medicine, Akita University Graduate School of Medicine, Japan

Yoko Yokoyama

Department of Internal Medicine, Division of Inflammatory Bowel Disease, Hyogo College of Medicine, Japan

GS1-05 Guideline of Apheresis in Cardiovascular Disease

Mariko Harada-Shiba

National Cerebral and Cardiovascular Center Research Institute, Japan

GS1-06 Guidelines on the use of therapeutic apheresis in pulmonary diseases: the potential treatment with direct hemoperfusion with polymyxin B-immobilized fiber column (PMX-DHP) for diffuse alveolar damage (DAD).

Shinji Abe

Department of Respiratory Medicine, Tokyo Medical University, Japan

Guideline Session 2 ガイドライン 2

15:30~17:00

Chair Hidenori Matsuo National Hospital Organization, Nagasaki National Hospital
Chair Bruce Sachais New York Blood Center

- GS2-01 Standardization of apheresis technologies**
Michio Mineshima
Department of Clinical Engineering, Tokyo Women's Medical University, Tokyo, Japan
- GS2-02 Apheresis guideline in Japan for management and treatment of pemphigus, bullous pemphigoid and toxic epidermal necrolysis**
Mariko Seishima
Department of Dermatology, Gifu University Graduate School of Medicine, Japan
- GS2-03 Japanese apheresis guidelines for the management and treatment of generalized pustular psoriasis, pustulosis palmoplantaris and psoriasis arthropathica.**
Miho Hatanaka
Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
- GS2-04 JSFA guidelines for hematological disorders**
Yasunori Ueda
Department of Hematology/Oncology, Transfusion and Hemapheresis Center Kurashiki Central Hospital Okayama, Japan
- GS2-05 JSFA Guidelines 2020 for Neurological Diseases**
Kyoichi Nomura
Department of Neurology, Saitama Medical Center, Saitama Medical University, Japan
- GS2-06 Description of new guidelines for therapeutic apheresis in the field of rheumatic disease.**
Makio Kusaoi
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
- GS2-07 American Society for Apheresis (ASFA) Guidelines for Apheresis**
Bruce Sachais
New York Blood Center, USA

Room D

Symposium 10 LDL

9:00~10:30

Lowering Lp(a)

Chair Wolfgang Ramlow Apheresis Center Rostock

Chair Beate Jaeger

Chair Atsushi Nohara Clinical Genetics, Ishikawa Prefectural Central Hospital

SY10-01 Lipoprotein(a)-Risk Marker and Therapeutic Target

Reinhard Klingel

Apheresis Research Institute, Cologne and 1st Department of Internal Medicine, University of Mainz, Germany

SY10-02

Beate Jaeger

SY10-03 Antisense and RNA interference drug therapy for the reduction of Lp(a) levels

Patrick M. Moriarty

University of Kansas Medical Center, USA

SY10-04 Effect of PCSK9i on Lp(a)

Atsushi Nohara

Clinical Genetics, Ishikawa Prefectural Central Hospital, Japan

Symposium 11 LDL

10:45~12:15

Position of Lipoprotein Apheresis after Recent Development of Lipid Lowering Drugs

Chair Patrick M. Moriarty University of Kansas Medical Center Kansas City, KS

Chair Mariko Harada-Shiba National Cerebral and Cardiovascular Center Research Institute

SY11-01 Treatment of FH in Japan

Hisashi Makino

The Department of Diabetes and Lipid Metabolism, National Cerebral and Cardiovascular Center, Osaka, Japan

SY11-02 Treatment of Familial Hypercholesterolemia in the United States

P. Barton Duell

Knight Cardiovascular Institute, Oregon Health and Science University, USA

SY11-03

Wolfgang Ramlow

SY11-04 Characterization of patients being treated with lipoprotein apheresis (LA) at the

Dresden LA center

Ulrich A Julius

Department of Internal Medicine III, University Hospital at the Technische Universität Dresden, Germany

Luncheon Seminar 5

12:30~13:30

Sponsored by Kaneka Medix Corp. 株式会社カネカメディックス

CARTについて考える

Chair 花房 規男 Norio Hanafusa 東京女子医科大学病院血液浄化療法科

- LS5-01 **ポンプ式腹水濾過濃縮再静注法 (CART) における安全管理**
Safety management in CART using pump for the driving force
大久保 淳
東京医科歯科大学 医学部附属病院MEセンター

- LS5-02 **有効性の高いCARTについて考える**
What is highly effective CART?
上條 祐司
信州大学医学部附属病院 血液浄化療法部

Symposium 12 CART /Ascites 腹水治療

15:30~16:30

CART, Its Current Status and Prospect for the Future Leaps

Chair Norio Hanafusa Tokyo Women's Medical University

Chair Yuji Kamijo Department of Nephrology, University School of Medicine

- SY12-01 **Verification of serum albumin elevating effect of cell-free and concentrated ascites reinfusion therapy for ascites patients**

Yosuke Yamada

Department of Nephrology, Shinshu University School of Medicine, Nagano, Japan

- SY12-02 **Characteristics and methods of the cell-free and concentrated ascites reinfusion therapy (CART) procedure in Japan**

Atsushi Ohkubo

Medical Engineering Center, Medical Hospital of Tokyo Medical and Dental University, Japan

- SY12-03 **Cell-free and Concentrated Ascites Reinfusion Therapy (CART) against malignancy-related ascites**

Tetsuya Ito

Department of Palliative Care, Japanese Red Cross Medical Center, Tokyo, Japan

- SY12-04 **Safety and quality control for filtered and concentrated ascites reinfusion therapy**

Taiju Utsugisawa

Department of Transfusion Medicine and Cell Processing, Tokyo Women's Medical University, Tokyo, Japan

Evening Seminar 3

17:05~18:05

Sponsored by Japan Blood Products Organization 一般社団法人 日本血液製剤機構

アフェリシス療法におけるアルブミン置換の実際

Chair 伊藤孝史 島根大学医学部附属病院 腎臓内科(島根大)

- ES3-01 **PE・SePEにおける置換液 -使用アルブミン濃度と希釈液-**

Appropriate diluted albumin solution as replacement fluids in PE and SePE

大久保淳

東京医科歯科大学医学部附属病院 MEセンター

- ES3-02 **SePEにおけるアルブミン置換の実際**

Clinical management of albumin replacement in selective plasma exchange

速見浩士

鹿児島大学病院 血液浄化療法部

Room B-1

Symposium 13 Hematology /Transfusion 血液・輸血 1

9:00~10:30

Hemapheresis and cellular therapy-state of the art and clinical applications-1

Chair Bruce Sachais New York Blood Center
 Chair Yasunori Ueda Kurashiki Central Hospital

- SY13-01 Overview of Cellular Therapy and the Critical Role for Apheresis Professionals**
 Bruce Sachais
 New York Blood Center, USA
- SY13-02 Cellular Collections for Immunotherapy, Perspective from a Large Academic Center**
 Nicole Aqui
 Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
- SY13-03**
 Christina (Chrissy) Anderson
- SY13-04 Recent advances in diagnosis and treatment of light-chain (AL) amyloidosis**
 Nobuhiro Tsukada
 Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan

Symposium 14 Hematology /Transfusion 血液・輸血 2

10:45~12:15

Hemapheresis and cellular therapy-state of the art and clinical applications-2

Chair Bruce Sachais New York Blood Center
 Chair Yasunori Ueda Kurashiki Central Hospital

- SY14-01 Autotransplantation for POEMS syndrome**
 Masahiro Takeuchi
 Department of Hematology, Chiba University Hospital, Chiba, Japan
- SY14-02 Update on granulocyte transfusions, including granulocytapheresis and clinical effectiveness**
 Satoshi Yoshihara
 Department of Transfusion Medicine and Cellular Therapy, Japan
- SY14-03 Plasmapheresis for the treatment of acquired thrombotic thrombocytopenic purpura**
 Yasunori Ueda
 Department of Hematology/Oncology, Transfusion and Hemapheresis Center Kurashiki Central Hospital Okayama, Japan
- SY14-04 atypical hemolytic uremic syndrome**
 Akira Ashida
 Department of Pediatrics, Osaka Medical College, Japan

Luncheon Seminar 6

12:30~13:30

Sponsored by Recordati Rare Diseases Japan K.K. レコルダティ・レア・ディシーズ・ジャパン

ホモ接合体を含む家族性高コレステロール血症のアップデート ～LDL-ApheresisとMTP阻害剤治療～

Updates on familial hypercholesterolemia (FH) including HoFH ～Treatment with LDL-Apheresis and MTP Inhibitor～

Chair 斯波 真理子 国立循環器病研究センター研究所 病態代謝部

- LS6-01** PCSK9阻害薬効果不十分な家族性高コレステロール血症 -ロミタピドとアフエレンシス治療の効果-

Treatment efficiency of uncontrolled familial hypercholesterolemia with lomitapide and apheresis-

稲垣 恭子

日本医科大学大学院医学研究科 内分泌糖尿病代謝内科学

- LS6-02** 家族性高コレステロール血症ホモ接合体症例に対するロミタピドとPCSK9阻害剤の協調効果

Synergistic effect of Lomitapide and PCSK9 inhibitor on familial hypercholesterolemia homozygote

太崎 博美

JR九州病院 循環器内科

Symposium 15 Nephrology 腎疾患

15:30~17:00

Apheresis for kidney disease

Chair Andre Kaplan University of Connecticut

Chair Takafumi Ito Division of Nephrology, Shimane University Hospital

- SY15-01** Therapeutic Apheresis in the Field of Nephrology - Future Direction and Missions of Nephrologists

Norio Hanafusa

Department of Blood Purification, Tokyo Women's Medical University, Tokyo, Japan

- SY15-02** Apheresis for nephrotic syndrome

Kengo Furuichi

Department of Nephrology, Kanazawa Medical University, Uchinada, Japan

- SY15-03** Apheresis for Focal Segmental Glomerulosclerosis

Andre A. Kaplan

University of Connecticut Health Center, Farmington, CT, USA

- SY15-04** Current status of Apheresis in the practice of Rapidly Progressive Glomerulonephritis in Japan

Shuzo Kaneko

The department of Nephrology, University of Tsukuba, Ibaraki, Japan

- SY15-05** Efficacy of selective plasma exchange at pre-transplant desensitization of ABO-incompatible kidney transplantation

Toshihide Naganuma

Department of Urology, Osaka City University, Osaka, Japan

Room B-2

English Oral 2 Nephrology /others 腎疾患 他 9:00~10:00

Chair Eriko Kinugasa Showa University Northern Yokohama Hospital

E02-01 Comparing the Outcomes of Desensitization for ABO Incompatible and HLA Incompatible Kidney Transplantation.

Natavudh Townamchai

Division of Nephrology, Department of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand

E02-02 Clinical outcome of the apheresis therapy for acute antibody-mediated rejection after kidney transplantation in our institute.

Yasushi Mochizuki

Division of Blood Purification, Nagasaki University Hospital, Japan

E02-03 Cost analysis of therapeutic plasma exchange procedure at Middlemore Hospital, New Zealand

Yvonne YL Lee

Health Economic and Market Access, Terumo BCT Asia, Singapore

Japanese Oral 3 膠原病・リウマチ・他 Collagen Disease/Rheumatology/other 10:45~12:00

Chair 根本 卓也 Takuya Nemoto 順天堂大学 医学部 膠原病内科

J03-01 抗リン脂質抗体症候群に対して血漿交換を施行した3例

野畑 宏信

愛知医科大学 腎臓・リウマチ膠原病内科

J03-02 当院における全身性強皮症に対する

PSL+IVCY+DFPPの皮膚病変への改善効果の検討

片桐 大輔

国立国際医療研究センター病院 腎臓内科

J03-03 抗MDA5抗体陽性皮膚筋炎合併急速進行性間質性肺炎6症例に対するアフェレシスの経験

齋藤 友広

昭和大学医学部 内科学講座 腎臓内科学部門

J03-04 免疫チェックポイント阻害薬による免疫関連副作用に対するアフェレシスの有用性

根本 卓也

順天堂大学 医学部 膠原病内科

J03-05 置換液にアルブミンを併用し単純血漿交換で治療し得た血栓性微小血管障害症の一例

鍵谷 真希

大阪医科大学附属病院 血液浄化センター

English Oral 3 Collagen Disease/Rheumatology/others	14:00~15:30
---	-------------

Chair Makio Kusaoi Department of Internal Medicine and Rheumatology,
Juntendo University School of Medicine

- EO3-01 Prognosis of anti-MDA5 antibody positive clinically amyopathic dermatomyositis treated with plasma exchange; a case series of single center experience.**
Satoshi Kumakura
Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University, Sendai, Japan
- EO3-02 Case series: Successful treatment of Adult Onset Still's Disease (AOSD) using Plasma Exchange**
Fumika Homma
Division of Nephrology, Department of Internal Medicine, Teikyo University, Tokyo, Japan
- EO3-03 Economic benefits of centrifugal method in therapeutic plasma exchange: experience from private hospitals in India**
Yvonne YL Lee
Health Economic and Market Access, Terumo BCT Asia, Singapore
- EO3-04 The economic impact of centrifugal technique for therapeutic plasma exchange; public hospital perspective**
Tsai Yun Chen
Hematology Department, National Cheng Kung University Hospital, Taiwan
- EO3-05 Effectiveness of Therapeutic Plasma Exchange in the Treatment of Catastrophic Antiphospholipid Syndrome: A 15-year Retrospective Review.**
Jan C. Hofmann
Department of Medicine, California Pacific Medical Center, San Francisco, California, U.S.A.
- EO3-06 The efficacy of plasmapheresis for multiple sclerosis and neuromyelitis optica unresponsive to steroid-pulse therapy and its immunological prognostic markers**
Youwei Lin
Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan

State of the Art 4 Hepatology 肝疾患	15:30~16:30
-----------------------------------	-------------

Chair Kyou-Sup Han Medical Director of the Blood Bank,
Seoul National University Hospital

- SA4-01 Artificial liver treatment improves survival in patients with acute-on-chronic liver failure: A prope**
Jun Li
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- SA4-02 1,5-Anhydroglucitol predicts proliferation of liver parenchymal cells during liver regeneration**
Yalei Zhao
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

SA4-03 Transcriptomics identifies immune-metabolism disorder in development and progression of hepatitis B virus-related acute-on-chronic liver failure

Jun Li

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

SA4-04 Aristolochic Acid I induced FLAP/CysLTs/CYLD signaling axis in premalignant liver tissue

Kunkai Su

State Key Laboratory and National Clinical Research Center for Infectious Diseases, 1st Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

10月18日(金)
プログラム

10月19日(土)
プログラム

10月20日(日)
プログラム

特別企画

シンポジウム

ガイドライン
セッション

ミニチュア
アエリス
レクチャー

技術講習会

EUSFA
Workshop

アエリス
世界の
事情

一般演題
(英語口演)

一般演題
(日本語口演)

一般演題
(ポスター)

セミナー

索引

Room E

Japanese Oral 4 技術1 血球除去 Technology 1

9:00~10:30

Chair 大久保 淳 Atsushi Okubo 東京医科歯科大学医学部附属病院 ME Center,

- J04-01 アフレシス治療における今後の可能性～経験則、方法論から導き出された35年を振り返る～
北野達也
星城大学 経営学部 健康マネジメント系 医療マネジメントコース/星城大学大学院 健康支援学研究科 医療安全管理学
- J04-02 GMA治療過程におけるアダカラム酢酸セルロースビーズの顆粒球付着状況の変化
奥野 敏行
済生会熊本病院臨床工学部門
- J04-03 GMA治療におけるシャントマップ・エコーガイド下穿刺を用いたアクセス確保の有用性について
湊 千笑
社会医療法人母恋 日鋼記念病院 臨床工学室
- J04-04 シングルニードル法を用いた顆粒球吸着療法における治療時間と吸着効率の検討
月安 啓一郎
社会医療法人北楡会 北楡病院 臨床工学技術科
- J04-05 下肢抹動脈疾患 (PAD) を合併する血液透析患者に対する加温式リサキュレーション法 (DFT) の効果について
津田 圭一
東邦大学医療センター大森病院 臨床工学部
- J04-06 アフレシス療法に伴う有害事象とその対処法の実態調査
柳澤 一樹
JA長野厚生連 佐久総合病院 佐久医療センター 臨床工学科

Japanese Oral 5 技術2 その他 Technology /others

10:45~12:15

Chair 岩本ひとみ Hitomi Iwamoto 社会医療法人天神会法人本部総務部

- J05-01 新鮮凍結血漿とアルブミン溶液併用による単純血漿交換療法時のフィブリノゲン変化率に関する検討
鶴田 友加里
神戸大学医学部附属病院 臨床工学部門
- J05-02 二重膜濾過血漿交換に溶質移動シミュレーションを活用した溶質濃度予測の有用性
小田巻 聡
日本赤十字社医療センター 臨床工学技術課
- J05-03 遠心法による血漿交換療法と膜分離法による血漿交換療法の比較
山本 裕子
東京医科歯科大学医学部附属病院 MEセンター
- J05-04 遠心分離法を用いたLDL吸着療法の試み
大久保 淳
東京医科歯科大学医学部附属病院 MEセンター

J05-05 ABO血液型不適合腎移植における二重濾過血漿交換（DFPP）および選択的血漿交換（SePE）の比較検討

早崎 裕登
鹿児島大学病院 臨床技術部 臨床工学部門

Japanese Oral 6 腎疾患 腎移植 Nephrology/Transplantation

13:40~15:10

Chair 中村 司 Tsukasa Nakamura 新松戸中央総合病院 腎臓内科

J06-01 血液型不適合生体腎移植前のアフェレーシス法の違いによる血液型抗体除去効果と問題点の検討

安藤 忠助
大分大学 医学部 腎泌尿器外科学

J06-02 経皮的腎動脈形成術後に発症し、血液交換が奏功した血栓性微小血管症

山口 健太
JCHO仙台病院 腎センター内科

J06-03 ステロイド抵抗性微小変化型ネフローゼ症候群に対し、LDL吸着療法とシクロスポリンの相乗作用が奏功した一例

島 久登
社会医療法人川島会川島病院

J06-04 AcuFil Multi 55X-II専用回路SHG-1.0(PS)とPrismaflexHFセット(PAES)の比較検討

徳吉 光示
東京西徳洲会病院 臨床工学科

J06-05 当院におけるFSGSに対する腎移植術前LDLアフェレーシスの成績と検討

杉本 龍亮
京都府立医科大学付属病院 移植一般外科

J06-06 ドナー特異的抗HLA抗体陽性生体腎移植の血漿交換施行時に副作用を合併した1例

近藤 佑哉
J A長野厚生連 佐久医療センター 臨床工学科

技術講習会1 Technical Talk 1

15:30~17:00

Chair 岩本ひとみ Hitomi Iwamoto 社会医療法人天神会法人本部総務部

TT1-01 血漿交換療法

山本 裕子
東京医科歯科大学 医学部附属病院 MEセンター

TT1-02 二重濾過血漿分離交換法

太田 稔
北海道大学病院 ME機器管理センター

Room D 前 ホワイエ

10月18日(金)
フロラム10月19日(土)
フロラム10月20日(日)
フロラム

特別企画

シンポジウム

ガイドライン
セッションアフェリシス
ミニチュアセミナー

技術講習会

ESFA
Workshop世界の
アフェリシス事情一般演題
(英語口演)一般演題
(日本語口演)一般演題
(ポスター)

セミナー

索引

Poster Presentation 3 技術3 Technology

10:30~11:40

Chair 佐藤 元美 Motoyoshi Sato 新城市民病院 腎臓内科・人工透析センター
Shinshiro Municipal Hospital

- PP3-01** **Effect of DFPP on various plasma components according to different plasma fractionator: a prospective monocentric observational cohort study.**
olivier Moranne
Nephrology Dialysis Apheresis Department, CHU Nimes, University Montpellier-Nimes, France
- PP3-02** **Impact of non-appendix cancer-specific death on overall survival: A competing risk analysis**
Kaicen Wang
The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
- PP3-03** **磁性粒子を利用した透析訓練システムのアフェリシスへの応用に関する検討
Utilization of the newly established dialysis training system using magnetic particles for apheresis training**
小幡 大輔
JCHO札幌北辰病院
- PP3-04** **自家末梢血幹細胞採取(APBSCC)における採取方法の違いについての後方視的比較検討
Retrospective comparison and examination about difference of collection method in Autologous Peripheral Blood Stem Cell Collection (APBSCC)**
須藤 弘樹
横浜市立市民病院 臨床工学部
- PP3-05** **当院におけるアフェリシスの施行状況 (2008年~2018年)
Our experiences with plasm apheresis therapy from 2008 to 2018.**
坂井 健太郎
社会医療法人 雪の聖母会 聖マリア病院 腎臓内科
- PP3-06** **維持透析患者における重症下肢虚血の長期治療成績
Long-term results of treatment for critical limb ischemia in maintenance dialysis patients**
佐藤 元美
新城市民病院 腎臓内科
- PP3-07** **日本の臨床工学技士養成校におけるアフェリシス領域での教育法について
The Education Method in Apheresis in The Clinical Engineering Technical Training School of Japan**
森崎 綾
冲永学園 帝京短期大学 専攻科 臨床工学専攻

Chair 宮本 勝一 Katsuichi Miyamoto 近畿大学医学部 脳神経内科
Faculty of Medical Science, Kindai University

- PP4-01 Red cell exchange versus blood transfusion therapy: improving patient outcomes**
Samantha Easton
Mater Cancer Care Centre, Mater Health Services, South Brisbane, Queensland, Australia
- PP4-02 Successful Treatment with Early Plasmapheresis in Secondary Hemophagocytic Lymphohistiocytosis(HLH) with Cytomegalovirus Infection in Myasthenia Gravis**
Kuan-Yu Lin
Department of Neurology, Shin Kong WHS Memorial Hospital, Taipei, Taiwan
- PP4-03 Treatment of Stiff-person syndrome using double filtration plasmapheresis and immunoadsorption**
Sergei Bardakov
Department of Nephrology and Extracorporeal haemocorrection of Medical Military Academy, St.Petersburg, Russia
- PP4-04 Plasma Exchange to Myopathy without Optic Neuritis or Quadriplegia in Neuro-myelitis Optica Spectrum Disorders: A Case Report**
Yoshito Yamaguchi
Division of Nephrology, Department of Internal Medicine, Otemae Hospital, Japan
- PP4-05 Efficacy of plasmapheresis for patients with stiff person syndrome. Summary of case-study reports.**
Akihito Tanaka
Division of Nephrology, Nagoya University Hospital, Nagoya, Japan
- PP4-06 単純血漿交換及びリツキシマブ併用療法が奏功した再発性の後天性血栓性血小板減少性紫斑病の一例**
A case of relapsing acquired thrombotic thrombocytopenic purpura successfully treated with simple plasma exchange and rituximab combination therapy
小倉 央行
金沢大学大学院 腎臓内科学
- PP4-07 自己免疫性辺縁系脳炎に対する血液浄化療法の有効性**
Efficacy of plasmapheresis for autoimmune limbic encephalitis.
古谷 真由美
埼玉医科大学総合医療センター 神経内科